Subjects will be randomized into 4 study groups: 1. Placebo; 2. Anastrazole and Testosterone; 3. Dutasteride and Testosterone; and 4. Testosterone only. A 2 step euglycemic clamp, body composition by dual X-ray absorptiometry scan, hormone and lipid assays will be performed to monitor metabolic effects of each treatment group. We hypothesize that increasing testosterone levels would increase lean mass, decrease fat mass and improve insulin sensitivity. We further hypothesize that improvements in the metabolic profile would decrease with anastrazole and improve with dutasteride, given in conjunction with T administration.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Enrollment
57
Arimidex 1mg daily
Testim 10g daily
Avodart 2.5mg daily
Acyline 300 µg/kg subcutaneous injections every 2 weeks
University of California, San Diego
San Diego, California, United States
VA San Diego Healthcare System
San Diego, California, United States
insulin sensitivity
Time frame: 14 weeks
body composition
Time frame: 14 weeks
lipid profile
Time frame: 14 weeks
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.